A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Any underlying chronic conditions were assessed to be in stable condition per the investigator's judgment
Females: Not pregnant or a breast feeding and not a woman of childbearing potential (WOCBP) or a WOCBP agrees to use contraception or remain abstinent
You may not be if
History of IPD or other culture-positive pneumococcal disease
Known or suspected impairment of immunological function
Receipt of systemic corticosteroids or immunosuppressive therapy
Received any pneumococcal vaccine \<12 months prior to enrollment
Prior administration of PCV15 or PCV20
Received any influenza vaccine \<6 months prior to enrollment
Clareo Health | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
